Literature DB >> 31599606

A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: Treatment efficacy by contrast condition.

Molly Magill1, Lara Ray2, Brian Kiluk3, Ariel Hoadley4, Michael Bernstein4, J Scott Tonigan5, Kathleen Carroll3.   

Abstract

OBJECTIVE: This meta-analysis examined 30 randomized controlled trials (32 study sites; 35 study arms) that tested the efficacy of cognitive-behavioral therapy (CBT) for alcohol or other drug use disorders. The study aim was to provide estimates of efficacy against three levels of experimental contrast (i.e., minimal [k = 5]; nonspecific therapy [k = 11]; specific therapy [k = 19]) for consumption frequency and quantity outcomes at early (1 to 6 months [kes = 41]) and late (8+ months [kes = 26]) follow-up time points. When pooled effect sizes were statistically heterogeneous, study-level moderators were examined.
METHOD: The inverse-variance weighted effect size was calculated for each study and pooled under random effects assumptions. Sensitivity analyses included tests of heterogeneity, study influence, and publication bias.
RESULTS: CBT in contrast to minimal treatment showed a moderate and significant effect size that was consistent across outcome type and follow-up. When CBT was contrasted with a nonspecific therapy or treatment as usual, treatment effect was statistically significant for consumption frequency and quantity at early, but not late, follow-up. CBT effects in contrast to a specific therapy were consistently nonsignificant across outcomes and follow-up time points. Of 10 pooled effect sizes examined, two showed moderate heterogeneity, but multivariate analyses revealed few systematic predictors of between-study variance.
CONCLUSIONS: The current meta-analysis shows that CBT is more effective than a no treatment, minimal treatment, or nonspecific control. Consistent with findings on other evidence-based therapies, CBT did not show superior efficacy in contrast to another specific modality. (PsycINFO Database Record (c) 2019 APA, all rights reserved).

Entities:  

Mesh:

Year:  2019        PMID: 31599606      PMCID: PMC6856400          DOI: 10.1037/ccp0000447

Source DB:  PubMed          Journal:  J Consult Clin Psychol        ISSN: 0022-006X


  18 in total

1.  Initial testing of a computer-based simulation training module to support clinicians' acquisition of CBT skills for substance use disorder treatment.

Authors:  Nadine R Mastroleo; Laura Humm; Callon M Williams; Brian D Kiluk; Ariel Hoadley; Molly Magill
Journal:  J Subst Abuse Treat       Date:  2020-04-25

2.  Short- and long-term changes in substance-related coping as mediators of in-person and computerized CBT for alcohol and drug use disorders.

Authors:  Corey R Roos; Kathleen M Carroll; Charla Nich; Tami Frankforter; Brian D Kiluk
Journal:  Drug Alcohol Depend       Date:  2020-05-12       Impact factor: 4.492

3.  The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: an umbrella review and meta-analytic evaluation of recent meta-analyses.

Authors:  Falk Leichsenring; Christiane Steinert; Sven Rabung; John P A Ioannidis
Journal:  World Psychiatry       Date:  2022-02       Impact factor: 49.548

Review 4.  Targeting Unmet Clinical Needs in the Treatment of Alcohol Use Disorder.

Authors:  Falk W Lohoff
Journal:  Front Psychiatry       Date:  2022-06-09       Impact factor: 5.435

5.  Long-term efficacy of contingency management treatment based on objective indicators of abstinence from illicit substance use up to 1 year following treatment: A meta-analysis.

Authors:  Meredith K Ginley; Rory A Pfund; Carla J Rash; Kristyn Zajac
Journal:  J Consult Clin Psychol       Date:  2021-01

6.  Intensive longitudinal methods for studying the role of self-regulation strategies in substance use behavior change.

Authors:  Corey R Roos; Hedy Kober; Timothy J Trull; R Ross MacLean; Chung Jung Mun
Journal:  Curr Addict Rep       Date:  2020-08-13

7.  Characterizing the Variation of Alcohol Cessation Pharmacotherapy in Primary Care.

Authors:  Eden Bernstein; Ning Guo; Toyomi Goto; Michael B Rothberg
Journal:  J Gen Intern Med       Date:  2021-01-29       Impact factor: 6.473

8.  Do behavioral pharmacology findings predict clinical trial outcomes? A proof-of-concept in medication development for alcohol use disorder.

Authors:  Lara A Ray; Han Du; ReJoyce Green; Daniel J O Roche; Spencer Bujarski
Journal:  Neuropsychopharmacology       Date:  2020-11-24       Impact factor: 8.294

Review 9.  Approaching Alcohol Use Disorder After Liver Transplantation for Acute Alcoholic Hepatitis.

Authors:  Peng-Sheng Ting; Ahmet Gurakar; Jason Wheatley; Geetanjali Chander; Andrew M Cameron; Po-Hung Chen
Journal:  Clin Liver Dis       Date:  2021-05-26       Impact factor: 6.265

Review 10.  Can pharmacotherapy improve treatment outcomes in people with co-occurring major depressive and cocaine use disorders?

Authors:  Gustavo A Angarita; Hasti Hadizadeh; Ignacio Cerdena; Marc N Potenza
Journal:  Expert Opin Pharmacother       Date:  2021-06-23       Impact factor: 4.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.